The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) effectively lower plasma glucose (PG) concentration in patients with type 2 diabetes, but studies have suggested that circulating glucagon concentrations and endogenous glucose production (EGP) are increased by SGLT2i, possibly compromising their gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hædersdal, Sofie, Lund, Asger, Nielsen-Hannerup, Elisabeth, Maagensen, Henrik, van Hall, Gerrit, Holst, Jens J., Knop, Filip K., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679772/
https://www.ncbi.nlm.nih.gov/pubmed/33004472
http://dx.doi.org/10.2337/db20-0369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679772/
https://www.ncbi.nlm.nih.gov/pubmed/33004472
http://dx.doi.org/10.2337/db20-0369

Ejemplares similares